

# Finding CMV in Some Cancer Tumors Predicts Poor Survival Rates; CBCD Reviews a Study

*Human cytomegalovirus (CMV) infection increases the aggressiveness of some types of cancer. (1)*

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, July 16, 2015 /EINPresswire.com/ --

“Infected with the Cytomegalovirus (CMV)? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#) against the latent virus.” - Greg Bennett, CBCD

Research has shown that finding CMV in tumors increases the risk of a poor outcome in cancers, such as glioblastoma (a highly invasive brain tumor). (1) In fact, “Numerous previous studies have confirmed that CMV nucleic acids and genes (DNA) are present in more than 90% of some GBM tumors ... (and) ...existing data supports the idea that long-term, low-level CMV infection may promote the survival, stemness, and proliferation of glioma stem-like cells and could significantly contribute to GBM pathogenesis (progression of the disease).” (2) An important finding of one study showed that “CMV-infected glioma stem-like cells outlived their uninfected counterparts, and this extended survival was paralleled by an increased frequency of tumor sphere formation.” (2) Because of the clear relationship between CMV and cancer, “researchers are continuing to study the relationship between CMV, GBM, and other types of cancer, including prostate, colon, and breast cancer.” (2)



“Cytomegalovirus (CMV) is a common virus belonging to the herpes virus family, which infects 70%-100% of the world’s population. After a primary infection that is generally mild or asymptomatic in the immunocompetent host, this virus establishes latency.” (3) Latency is a condition where the virus replicates on a small scale and only produces a subset of its proteins.

Click for more information on [CMV symptoms](#).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the CMV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the CMV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Scientists discovered that “CMV proteins are expressed only in tumor cells, while non-tumor cells surrounding the tumor are CMV negative.”(5) Moreover, CMV causes “DNA damage and inhibits DNA repair mechanisms, induces oncogene expression and telomerase activity, induces inflammation and at the same time avoids recognition by the immune system.” (5)

“The virus is generally passed from infected people to others through direct contact with body fluids, such as urine, saliva, or breast milk. CMV is sexually transmitted. It can also be spread through transplanted organs and blood transfusions. People who are infected with CMV can shed the virus (pass the virus from their infected body fluids, such as urine, saliva, blood, and semen, into the environment). Young children often shed CMV for months after they first become infected.” (6).

What can individuals do if they are infected with CMV?

“Several drugs are approved for the treatment of HCMV infections in immunocompromised individuals. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. However, the use of these drugs in immunocompetent individuals is limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (See Pharmacology & Pharmacy, from September 2013) (4). In other words, the only drugs available are normally reserved for those who have a severely compromised immune system, such as those with HIV/AIDS. There are no drugs approved for those with a mostly healthy immune system.

In contrast, there are two natural antivirals with a formula that has been shown to reduce symptoms of a CMV infection in two separate post-marketing clinical studies. Those products are Gene-Eden-VIR and Novirin.

“Concerned individuals should get a CMV blood test. If positive, we recommend that they take Novirin or Gene-Eden-VIR. The formula of these natural antivirals was designed to help the immune system target the latent virus.” – Greg Bennett, CBCD

Those interested in learning new and interesting facts on CMV infection are encouraged to like the Gene-Eden-VIR Facebook page, here:

<https://www.facebook.com/GeneEdenVIR>

Follow us on Twitter, here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) O Fornara, J Bartek Jr, A Rahbar, J Odeberg, Z Khan, I Peredo, P Hamerlik, J Bartek, G Stragliotto, N Landázuri and C Söderberg-Nauclér "Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact" Cell Death & Differentiation , (3 July 2015) | doi:10.1038/cdd.2015.91

(2) VBIVaccines.com - "New Study Lends Support To Possible CMV-Glioblastoma Connection" - Published January 21, 2015

(3) Söderberg-Nauclér C and Johnsen JI "Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options." Published in advance, World J Exp Med. 2015 February 20; 5(1): 1-10.

<http://www.wjnet.com/2220-315x/full/v5/i1/1.htm>

(4) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90>

(5) Cytomegalovirus infection in brain tumors. Published on August 1, 2012.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429578/>

(6) CDC - Cytomegalovirus (CMV) and Congenital CMV Infection - Transmission. Last updated on July 28, 2010.

<http://www.cdc.gov/CMV/transmission.html>

Greg Bennett  
CBCD  
585-250-9999  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.



